The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants

PLoS Neglected Tropical Diseases

Volumn 10, Issue 12, 2016, Pages

  Kano, Flora S ^a   Souza Silva, Flávia A ^a   Torres, Leticia M ^a   Lima, Barbara A S ^a   Sousa, Taís N ^a   Alves, Jéssica R S ^a   Rocha, Roberto S ^a,b   Fontes, Cor J F ^c   Sanchez, Bruno A M ^c   Adams, John H ^d   Brito, Cristiana F A ^a   Pires, Douglas E V ^a   Ascher, David B ^a,e,f   Sell, Ana Maria ^g   Carvalho, Luzia H ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO LEÔNIDAS E MARIA DEANE   (Brazil)

^c FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DUFFY ANTIGEN RECEPTOR FOR CHEMOKINE; DUFFY BINDING PROTEIN; DUFFY BINDING PROTEIN 2; HLA ANTIGEN CLASS 2; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; BLOOD GROUP DUFFY SYSTEM; CARRIER PROTEIN; CELL SURFACE RECEPTOR; DARC PROTEIN, HUMAN; DUFFY ANTIGEN BINDING PROTEIN, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADULT; ARTICLE; BINDING ASSAY; COS-7 CELL LINE; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; DRIED BLOOD SPOT TESTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GENETIC VARIATION; GENOTYPE; GIEMSA STAIN; GLOBAL POSITIONING SYSTEM; HAPLOTYPE; HEALTH CARE SURVEY; HELPER CELL; HEREDITY; HLA TYPING; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALARIA; MALE; MICROSCOPY; MIDDLE AGED; PLASMODIUM VIVAX; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; STRUCTURAL PROTEOMICS; YOUNG ADULT; ALLELE; BLOOD; BLOOD GROUP DUFFY SYSTEM; BRAZIL; CHEMISTRY; COHORT ANALYSIS; ERYTHROCYTE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; MALARIA, VIVAX; METABOLISM; PARASITOLOGY;

ADULT; ALLELES; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BRAZIL; CARRIER PROTEINS; COHORT STUDIES; DUFFY BLOOD-GROUP SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FEMALE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HLA-DRB1 CHAINS; HUMANS; IMMUNOGLOBULIN G; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE;

EID: 85008631611     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005177     Document Type: Article

References (70)

1. Miller L, Mason S, Clyde D, McGinniss M, The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976, 295:302–304. doi: 10.1056/NEJM197608052950602778616
2. Wertheimer SP, Barnwell JW, Plasmodium-vivax interaction with the human Duffy blood-group glycoprotein—identification of a parasite receptor-like protein. Exp Parasitol. 1989, 69:340–350. 2680568
3. Adams JH, Hudson DE, Torii M, Ward GE, Wellems TE, Aikawa M, Miller LH, The Duffy receptor family of Plasmodium-knowlesi is located within the micronemes of invasive malaria merozoites. Cell. 1990, 63:141–153. 2170017
4. Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, Owour B, Luckhart S, Wirtz RA, Barnwell JW, Rosenberg R, Evidence for transmission of Plasmodium vivax among a Duffy antigen negative population in Western Kenya. Am J Trop Med Hyg. 2006, 75:575–581. 17038676
5. Cavasini CE, Mattos LC, Couto AA, Bonini-Domingos CR, Valencia SH, Neiras WC, Alves RT, Rossit AR, Castilho L, Machado RL, Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception?Trans R Soc Trop Med Hyg. 2007, 101:1042–1044. doi: 10.1016/j.trstmh.2007.04.01117604067
6. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, Thonier V, Carod JF, Domarle O, Colin Y, et al: Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA. 2010, 107:5967–5971. doi: 10.1073/pnas.091249610720231434
7. Souza-Silva FA, Torres LM, Santos-Alves JR, Tang ML, Sanchez BA, Sousa TN, Fontes CJ, Nogueira PA, Rocha RS, Brito CF, et al: Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-Duffy binding protein II (DBPII) immunity. PLoS One. 2014, 9:e93782. doi: 10.1371/journal.pone.009378224710306
8. Sousa TN, Kano FS, Brito CF, Carvalho LH, The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon. Mem Inst Oswaldo Cruz. 2014, 0:25–30. 24863975
9. Michon P, Fraser T, Adams JH, Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun. 2000, 68:3164–3171. 10816459
10. Ceravolo IP, Souza-Silva FA, Fontes CJF, Braga EM, Madureira AP, Krettli AU, Souza JM, Brito CFA, Adams JH, Carvalho LH, Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission. Scand J Immunol. 2008, 67:270–278. doi: 10.1111/j.1365-3083.2007.02059.x18226014
11. King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, Zimmerman PA, Cole-Tobian JL, Mueller I, Chitnis CE, Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci USA. 2008, 105:8363–8368. doi: 10.1073/pnas.080037110518523022
12. Chootong P, Panichakul T, Permmongkol C, Barnes SJ, Udomsangpetch R, Adams JH, Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand. PLoS One. 2012, 7:e35769. doi: 10.1371/journal.pone.003576922558221
13. Souza-Silva FA, da Silva-Nunes M, Sanchez BA, Ceravolo IP, Malafronte RS, Brito CF, Ferreira MU, Carvalho LH, Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon. Am J Trop Med Hyg. 2010, 82:185–193. doi: 10.4269/ajtmh.2010.08-058020133990
14. Ceravolo I, Sanchez B, Sousa T, Guerra B, Soares I, Braga E, McHenry A, Adams J, Brito C, Carvalho L, Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol. 2009, 156:502–510. doi: 10.1111/j.1365-2249.2009.03931.x19438604
15. Maestre A, Muskus C, Duque V, Agudelo O, Liu P, Takagi A, Ntumngia FB, Adams JH, Sim KL, Hoffman SL, et al: Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC). PLoS One. 2010, 5:e11437. doi: 10.1371/journal.pone.001143720664684
16. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, Siddiqui A, Howes RE, da Silva-Nunes M, Ferreira MU, Zimmerman PA, Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad Sci USA. 2011, 108:20113–20118. doi: 10.1073/pnas.110962110822123959
17. Garamszegi LZ, Global distribution of malaria-resistant MHC-HLA alleles: the number and frequencies of alleles and malaria risk. Malar J. 2014, 13:349. doi: 10.1186/1475-2875-13-34925187124
18. Good MF, Miller LH, Kumar S, Quakyi IA, Keister D, Adams JH, Moss B, Berzofsky JA, Carter R, Limited immunological recognition of critical malaria vaccine candidate antigens. Science. 1988, 242:574–577. 2902690
19. Quakyi IA, Otoo LN, Pombo D, Sugars LY, Menon A, De Groot AS, Johnson A, Alling D, Miller LH, Good MF, Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens. Am J Trop Med Hyg. 1989, 41:125–134. 2672834
20. Taylor RR, Egan A, McGuinness D, Jepson A, Adair R, Drakely C, Riley E, Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol. 1996, 8:905–915. 8671680
21. Ferreira AR, Singh B, Cabrera-Mora M, Magri De Souza AC, Queiroz Marques MT, Porto LC, Santos F, Banic DM, Calvo-Calle JM, Oliveira-Ferreira J, et al: Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1*/DQB1* in malaria exposed individuals from the Brazilian Amazon. PLoS One. 2014, 9:e105828. doi: 10.1371/journal.pone.010582825148251
22. de Castro MC, Monte-Mór RL, Sawyer DO, Singer BH, Malaria risk on the Amazon frontier. Proc Natl Acad Sci USA. 2006, 103:2452–2457. doi: 10.1073/pnas.051057610316461902
23. Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, Nogueira PA, Goncalves AQ, Fontes CJ, Soares IS, et al: Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region. Trop Med Int Health. 2012, 17:989–1000. doi: 10.1111/j.1365-3156.2012.03016.x22643072
24. Organizatio WH: World Malaria Report 2014. pp. 242; 2014:242.
25. Mangold K, Manson R, Koay E, Stephens L, Regner M, Thomson RJ, Peterson L, Kaul K, Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol. 2005, 43:2435–2440. doi: 10.1128/JCM.43.5.2435-2440.200515872277
26. Ntumngia FB, Schloegel J, Barnes SJ, McHenry AM, Singh S, King CL, Adams JH, Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies. Infect Immun. 2012, 80:1203–1208. doi: 10.1128/IAI.05924-1122215740
27. Ceravolo IP, Bruna-Romero O, Braga EM, Fontes CJF, Brito CFA, Souza JM, Krettli AU, Adams JH, Carvalho LH, Anti-Plasmodium vivax Duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon. Am J Trop Med Hyg. 2005, 72:675–681. 15964949
28. Andreatta M, Karosiene E, Rasmussen M, Stryhn A, Buus S, Nielsen M, Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics. 2015, 67:641–650. doi: 10.1007/s00251-015-0873-y26416257
29. Ascher DB, Cromer BA, Morton CJ, Volitakis I, Cherny RA, Albiston AL, Chai SY, Parker MW, Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain. Biochemistry. 2011, 50:2611–2622. doi: 10.1021/bi101893w21348480
30. Ascher DB, Wielens J, Nero TL, Doughty L, Morton CJ, Parker MW, Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014, 4:4765. doi: 10.1038/srep0476524755925
31. Jafri M, Wake NC, Ascher DB, Pires DE, Gentle D, Morris MR, Rattenberry E, Simpson MA, Trembath RC, Weber A, et al: Germline Mutations in the CDKN2B Tumor Suppressor Gene Predispose to Renal Cell Carcinoma. Cancer Discov. 2015, 5:723–729. doi: 10.1158/2159-8290.CD-14-109625873077
32. Pires DE, Ascher DB, CSM-lig: a web server for assessing and comparing protein-small molecule affinities. Nucleic Acids Res. 2016, 44:W557–561. doi: 10.1093/nar/gkw39027151202
33. Pires DE, Chen J, Blundell TL, Ascher DB, In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity. Sci Rep. 2016, 6:19848. doi: 10.1038/srep1984826797105
34. Pires DE, Ascher DB, Blundell TL, DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach. Nucleic Acids Res2014, 42:W314–319. doi: 10.1093/nar/gku41124829462
35. Pires DE, Ascher DB, Blundell TL, mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics. 2014, 30:335–342. doi: 10.1093/bioinformatics/btt69124281696
36. Coelho MB, Ascher DB, Gooding C, Lang E, Maude H, Turner D, Llorian M, Pires DE, Attig J, Smith CW, Functional interactions between polypyrimidine tract binding protein and PRI peptide ligand containing proteins. Biochem Soc Trans. 2016, 44:1058–1065. doi: 10.1042/BST2016008027528752
37. Pires DE, Blundell TL, Ascher DB, mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance. Sci Rep. 2016, 6:29575. doi: 10.1038/srep2957527384129
38. Pires DE, Ascher DB, mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. Nucleic Acids Res. 2016, 44:W469–473. doi: 10.1093/nar/gkw45827216816
39. Perneger TV, What's wrong with Bonferroni adjustments. BMJ. 1998, 316:1236–1238. 9553006
40. Conneely KN, Boehnke M, So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet. 2007, 81:1158–1168. doi: 10.1086/52203617966093
41. Guo SW, Thompson EA, A Monte Carlo method for combined segregation and linkage analysis. Am J Hum Genet. 1992, 51:1111–1126. 1415253
42. Excoffier L, Slatkin M, Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995, 12:921–927. 7476138
43. Excoffier L, Lischer HE, Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 2010, 10:564–567. doi: 10.1111/j.1755-0998.2010.02847.x21565059
44. Xainli JL, Baisor M, Kastens W, Bockarie M, Adams JH, King CL, Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol. 2002, 169:3200–3207. 12218138
45. Chootong P, Ntumngia FB, VanBuskirk KM, Xainli J, Cole-Tobian JL, Campbell CO, Fraser TS, King CL, Adams JH, Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect Immun. 2010, 78:1089–1095. doi: 10.1128/IAI.01036-0920008533
46. Sousa TN, Tarazona-Santos EM, Wilson DJ, Madureira AP, Falcao PR, Fontes CJ, Gil LH, Ferreira MU, Carvalho LH, Brito CF, Genetic variability and natural selection at the ligand domain of the Duffy binding protein in Brazilian Plasmodium vivax populations. Malar J. 2010, 9:334. doi: 10.1186/1475-2875-9-33421092207
47. Chen E, Salinas ND, Huang Y, Ntumngia F, Plasencia MD, Gross ML, Adams JH, Tolia NH, Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein. Proc Natl Acad Sci USA. 2016, 113:6277–6282. doi: 10.1073/pnas.160048811327194724
48. Lima-Junior JC, Rodrigues-da-Silva RN, Banic DM, Jiang J, Singh B, Fabricio-Silva GM, Porto LC, Meyer EV, Moreno A, Rodrigues MM, et al: Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3alpha and MSP-9 in individuals from Brazilian endemic area. PLoS One. 2012, 7:e36419. doi: 10.1371/journal.pone.003641922649493
49. Salzano FM, Sans M, Interethnic admixture and the evolution of Latin American populations. Genet Mol Biol. 2014, 37:151–170. 24764751
50. Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy Fde S, Kohlrausch F, Magno LA, Montenegro RC, Moraes MO, et al: The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One. 2011, 6:e17063. doi: 10.1371/journal.pone.001706321359226
51. Kehdy FS, Gouveia MH, Machado M, Magalhaes WC, Horimoto AR, Horta BL, Moreira RG, Leal TP, Scliar MO, Soares-Souza GB, et al: Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci USA. 2015, 112:8696–8701. doi: 10.1073/pnas.150444711226124090
52. Storti-Melo LM, da Costa DR, Souza-Neiras WC, Cassiano GC, Couto VS, Povoa MM, Soares Ida S, de Carvalho LH, Arevalo-Herrera M, Herrera S, et al: Influence of HLA-DRB-1 alleles on the production of antibody against CSP, MSP-1, AMA-1, and DBP in Brazilian individuals naturally infected with Plasmodium vivax. Acta Trop. 2012, 121:152–155. doi: 10.1016/j.actatropica.2011.10.00922107686
53. Li ZK, Nie JJ, Li J, Zhuang H, The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine. 2013, 31:4355–4361. doi: 10.1016/j.vaccine.2013.06.10823887040
54. Posteraro B, Pastorino R, Di Giannantonio P, Ianuale C, Amore R, Ricciardi W, Boccia S, The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses. Vaccine. 2014, 32:1661–1669. doi: 10.1016/j.vaccine.2014.01.05724513009
55. Caillat-Zucman S, Gimenez JJ, Wambergue F, Albouze G, Lebkiri B, Naret C, Moynot A, Jungers P, Bach JF, Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int. 1998, 53:1626–1630.
56. Chitnis C, Miller L, Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med. 1994, 180:497–506. 8046329
57. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, et al: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008, 8:186–195. doi: 10.1038/sj.tpj.650045817505501
58. Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE, Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol. 2014, 32:2296–2303. doi: 10.1200/JCO.2013.52.986724687830
59. Fernandez CA, Smith C, Yang W, Date M, Bashford D, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, et al: HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood. 2014, 124:1266–1276. doi: 10.1182/blood-2014-03-56374224970932
60. Nunez C, Cenit MC, Alvarez-Lafuente R, Rio J, Fernandez-Arquero M, Arroyo R, Montalban X, Fernandez O, Oliver-Martos B, Leyva L, et al: HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-beta therapy in multiple sclerosis. J Med Genet. 2014, 51:395–400. doi: 10.1136/jmedgenet-2014-10234824748646
61. El-Manzalawy Y, Dobbs D, Honavar VG, In Silico Prediction of Linear B-Cell Epitopes on Proteins. Methods Mol Biol. 2017, 1484:255–264. doi: 10.1007/978-1-4939-6406-2_1727787831
62. Luo H, Ye H, Ng HW, Shi L, Tong W, Mendrick DL, Hong H, Machine Learning Methods for Predicting HLA-Peptide Binding Activity. Bioinform Biol Insights. 2015, 9:21–29.
63. Dai S, Murphy GA, Crawford F, Mack DG, Falta MT, Marrack P, Kappler JW, Fontenot AP, Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proc Natl Acad Sci U S A. 2010, 107:7425–7430. doi: 10.1073/pnas.100177210720356827
64. Pott GB, Palmer BE, Sullivan AK, Silviera L, Maier LA, Newman LS, Kotzin BL, Fontenot AP, Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol. 2005, 115:1036–1042. doi: 10.1016/j.jaci.2005.01.01915867863
65. Mack DG, Falta MT, McKee AS, Martin AK, Simonian PL, Crawford F, Gordon T, Mercer RR, Hoover MD, Marrack P, et al: Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease. Proc Natl Acad Sci U S A. 2014, 111:8553–8558. doi: 10.1073/pnas.140804811124912188
66. Naess S, Lie BA, Melum E, Olsson M, Hov JR, Croucher PJ, Hampe J, Thorsby E, Bergquist A, Traherne JA, et al: Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population. PLoS One. 2014, 9:e114486. doi: 10.1371/journal.pone.011448625521205
67. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L, Padyukov L, Klareskog L, Worthington J, et al: Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012, 44:291–296. doi: 10.1038/ng.107622286218
68. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH, A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A. 1992, 89:7085–7089. 1496004
69. Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A, Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature. 2006, 439:741–744. doi: 10.1038/nature0444316372020
70. Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, Owour B, Luckhart S, Wirtz RA, Barnwell JW, Rosenberg R, Evidence for transmission of Plasmodium vivax among a Duffy antigen negative population in Western Kenya. Am J Trop Med Hyg. 2006, 75:575–581.